Offres technologiques du CNRS

Retourner à la liste

Adenoviral coat protein delivery vehicles for use as a vaccine platform

CONTEXT

Infectious diseases continue to plague and decimate populations world-wide. Among the means at our disposal to counter this threat, vaccination has proven to be exceptionally powerful. Nonetheless, severe threats continue to challenge human health, notably also from emergent viruses that have adapted and emerged as new diseases. Recent such examples are the severe threat posed by Chikungunya and Zika insect-born viruses. Ideally, a vaccine will be safe, non-replicative, efficient, and tunable with the possibility to be produced easily at industrial scale.

TECHNICAL DESCRIPTION

The present invention relates to new adenoviral coat protein based delivery vehicles. They are based on a modified penton base protomers that assemble into VLPs. Exposed areas of the penton base proteins can be modified to allow the VLP to specifically bind to any target and/or to comprise any desired peptide epitope.

DEVELOPMENT STAGE

Available vaccine particle: displaying Chikungunya epitope 
In vivo (mice) PoC 

BENEFITS

Rapid production
Strong immune response
Safe
Optimized antigen presentation

INDUSTRIAL APPLICATIONS

The objective is to generate a pipeline in different domains: infectious diseases, veterinary applications, therapeutic vaccines in oncology. The developments could be conducted in the frame of a start-up.

For further information, please contact us (Ref 09073-01)

Notre référence : 09073-01 Téléchargement
Mots clés
  • Virus like particles (VLP)
  • vaccine vector
  • Chikungunya
Statut des brevets

European priority patent application filed on March the 31st , 2016 and entitled “Adenoviral coat protein derived delivery vehicles technical field of the invention”

Inventeurs

Pascal FENDER
Imre BERGER
Frédéric GARZONI

Statut Commercial

Exclusive or non-exclusive license

Laboratoire

Institut de Biologie Structurale (IBS) Grenoble, France